4-[3-[(5Z)-4-oxo-5-[(E)-3-phenylprop-2-enylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoylamino]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[3-[(5Z)-4-oxo-5-[(E)-3-phenylprop-2-enylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoylamino]benzoic acid
• 化学式: C₂₂H₁₈N₂O₄S₂
• 分子量: 438.5
• InChiKey: SXEBXUSHYQFNOY-DFBITEFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
  申请人：Phio Pharmaceuticals Corp.

  公开号：US10808247B2

  公开（公告）日：2020-10-20

  In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-κB p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.

  在一个方面，本发明公开了治疗神经退行性疾病的方法，包括向有需要的受试者施用治疗有效量的核酸分子和治疗有效量的小分子，该小分子可激活NF-κB p65并增加锰超氧化物歧化酶（MnSOD/SOD2）的表达和/或相关蛋白或酶的表达。
• METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH
  申请人：Rxi Pharmaceuticals Corporation

  公开号：US20180195066A1

  公开（公告）日：2018-07-12

  In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-κB p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.